Drug Trial Radar · NCT02973542
Ethosuximide to Treat IBS
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
162
Actual
Start
Feb 8, 2018
Primary completion
Mar 7, 2023
Study completion May 7, 2023
Sponsor
- Lead sponsor
- University Hospital, Clermont-FerrandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SFETD (Socièté Française d'Etude et de Traitement de la Douleur)
- First posted
- Nov 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Abdominal pain remains the most deleterious symptom for patients with irritable bowel syndrome (IBS) and is causing a significant alteration of their quality of life. The visceral hypersensitivity seems to be one of the key mechanisms that could explain the abdominal pain in these patients. Current treatments, mainly symptomatic, are of limited effectiveness, especially in terms of relief of abdominal pain. The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
Conditions
- Irritable Bowel Syndrome
Interventions
EthosuximideDrug
The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
PlaceboOther
The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30% reduction in abdominal painTime frame: through study completion, an average of 12 weeks.
- Score of 4 or 5 on the SGA scaleTime frame: through study completion, an average of 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU Clermont-Ferrand
Clermont-Ferrand, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.